Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH et al.
Lancet 2024; 403: 632-644.
This study included 157 patients with high risk of recurrence after surgical resection. After eighteen months, the addition of neoantigen therapy improved recurrence-free survival from 62 to 79 per cent, P=0.053. There were no serious side effects.
Comment: The start of vaccination therapy for melanoma.
3 May 2024
Read paperAcademy
Part of the charitable activity of the Foundation, BJS Academy is an online educational resource for current and future surgeons.
The Academy is comprised of five distinct sections: Continuing surgical education, Young BJS, Cutting edge, Scientific surgery and Surgical news. Although the majority of this is open access, additional content is available to BJS subscribers and strategic partners.
